OwnershipPublicly listed · Nasdaq: BEAMSEC EDGAR company record and tickers file (Nasdaq: BEAM) · checked Oct 28, 2026
Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessVerified public listingListed as Nasdaq: BEAM, per the SEC's company tickers file. A listing means shares trade publicly; it says nothing about whether they are a good investment.Source · checked Oct 28, 2026

Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Next scheduled recheck: Nov 27, 2026.

3developments published
—US federal obligations on record
2private-offering notices since 2019
Aug 4, 2026latest development

Profile

Legal name
Beam Therapeutics Inc.
Listing
Nasdaq BEAM
SEC industry code
Biological Products, (No Diagnostic Substances)
Incorporated
DE
Coverage
Filings + federal awards

Watch Beam Therapeutics

Anything new from Beam Therapeutics lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.

Follow this companyPreview a sample digest

Private offerings reported to the SEC (Form D)

A Form D is a notice a company files after selling securities without a public registration. Amount sold is cumulative for that offering as reported by the company; an amendment (D/A) updates an earlier notice, so rows are not added together. None of these is a valuation or an open offer.

FiledFormAmount soldOffering sizeFirst saleInvestorsExemptionRecord
Mar 26, 2019D/A$83.6 million$83.6 millionFeb 9, 201821Rule 506(b)SEC ↗
Mar 26, 2019D$135 million$135 millionNov 8, 201827Rule 506(b)SEC ↗